DOCSLIB.ORG

A Mechanism of Action of Gold in Rheumatoid Arthritis. A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Mechanism of Action of Gold in Rheumatoid Arthritis. A University of Rhode Island DigitalCommons@URI Open Access Dissertations 1980 A MECHANISM OF ACTION OF GOLD IN RHEUMATOID ARTHRITIS. A BIOCHEMICAL AND MORPHOLOGICAL INVESTIGATION OF THE DIRECT EFFECT OF GOLD SODIUM THIOMALATE (GST) ON HUMAN SYNOVIAL CELLS IN CULTURE Ronald Lee Goldberg University of Rhode Island Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss Recommended Citation Goldberg, Ronald Lee, "A MECHANISM OF ACTION OF GOLD IN RHEUMATOID ARTHRITIS. A BIOCHEMICAL AND MORPHOLOGICAL INVESTIGATION OF THE DIRECT EFFECT OF GOLD SODIUM THIOMALATE (GST) ON HUMAN SYNOVIAL CELLS IN CULTURE" (1980). Open Access Dissertations. Paper 150. https://digitalcommons.uri.edu/oa_diss/150 This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. A MECHANISM OF ACTION OF GOLD IN RHEUMATOID ARTHRITIS. A BIOCHEMICAL AND MORPHOLOGICAL INVESTIGATION OF THE DIRECT EFFECT OF GOLD SODIUM THIOMALATE (GST) ON HUMAN SYNOVIAL CELLS IN CULTURE BY RONALD LEE GOLDBER~ A DISSERTATION SUBMITTED IN PARTIAL - FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHTLOSOPHY IN PHARMACEUTICAL SCIENCES (PHARMACOLOGY AND TOXICOLOGY) UNIVERSITY OF RHODE ISLAND 19 80 DOCTOR OF PHILOSOPh'Y DISSERTATION OF RONALD LEE GOLDBERG Approved: Dissertation Major Dean of the Graduate School UNIVERSITY OF RHODE ISLAND 1980 ACKNOWLEDGEMENT The author wishes to express his sincere appreciation to Dr. George Fuller for his continuous guidance, encourage­ ment and understanding throughout the author's graduate studies. Sincere appreciation is expressed to Dr. Stephen Kaplan for his enthusiasm and direction on this work. Spe­ cial thanks are conveyed to Dr. Elizabeth La Due for her assistance on the morphological work. Acknowledged are Grant Jolly, John Ewell and Philip McGrath for the electron microscope and X-ray probe analysis work. Thanks and grati­ tude are extended to Dr. Dave Parrott for his instructions and assistance with the cell culture work. Gratitudes are extended to Lynn Matoney and Hank Turner for their assist­ ance with the cell culture work. To the author's parents, many thanks for their eternal support, confidence and en­ couragement. Financial support for this investigation was provided by a grant from the Rhode Island Chapter of The Arthritis Fou.~dation awarded to Dr. Stephen Kaplan and by a NIH Grant HL 16904 awarded to Dr. George Fuller. iv ABS.TRACT Goldberg, Ronald Lee. Ph.D., University of Rhode Island, 1980. A mechanism of action of gold in rheumatoid arthritis: a bio­ chemical and morphological investigation of the direct effect of gold sodium thiomalate (GST) on human synovial cells in cul­ ture. Major Professor: Dr. George C. Fuller. Gold sodium thiomalate (GST) effects on cultured rheuma- toid synovial cells were used as a model to investigate a mech- anism which can explain clinical benefits gained by patients from gold therapy. Synovial tissue obtained from patients with rheumatoid arthritis who were undergoing reconstructive joint surgery was used to obtain explant culture of synovial cells. The experiments described were performed on growing monolayer cultures during the second to fifth passages. Synovial cells were exposed to GST at pharmacologically relevant concentra- tions (10-100 uM). Vacuoles were found by phase contrast micro- scopy in synovial cells in culture after 2 days of exposure to 100 uM GST. The vacuoles,aurosomes, were found to contain electron dense material by electron microscopy that contained gold as identified by X-ray probe analysis. The structure of the aurosomes, electron dense lamellae structures in membrane bound vesicles, was found to be similar to those found in synovial tissue of patients with rheumatoid arthritis who had received gold therapy. The time course for gold accumulation in the cell layer paralleled with aurosome formation and the degree of inhibition of [ 3H]thymidine incorporation into DNA. ii DNA synthesis, DNA content and cell number were decreased in a dose dependent manner after synovial cells were exposed to GST containing medium. The synthesis of medium proteins per flask by synovial cells was decreased in a dose dependent manner with collagen decreased to a greater extent. The per­ centage of collagen to total protein synthesized by synovial cells was decreased in a dose dependent manner. A biphasic response of an increase followed by a decrease of proteins synthesized per cell or per DNA unit was found due to GST ex­ posure. The increase in collagen protein per cell was found to be predominantly type I collagen. The percentage of type III collagen decreased due to synovial cells exposure to GST containing medium. Removal of GST from the medium resulted in recovery of biochemical parameters at low concentrations and a partial recovery at high concentration. Neither auro­ somes nor gold could be completely removed from synovial cells after medium changes and subculturing. An important thera­ peutic mechanism of action of gold in the treatment of pa­ tients with rheumatoid arthritis may be by directly inhibit­ ing synovial cells proliferation and altering protein syn­ thesis by synovial cells to a nonconducive matrix for pannus expansion. iii TABLE OF CONTENTS PAGE ABSTRACT ••... ii ACKNOWLEDGEMENTS .• ~ . iv TABLE OF CONTENTS . v LIST OF TABLES. vii LIST OF FIGURES . viii CHAPTER I. INTRODUCTION ... ~ 1 II. LITERATURE SURVEY:' . 3 A. Rh.eumatoid Arthritis • 3 1. Etiology· of rheumatoid arthritis 3 2. pathogenesis of rh.eumatoid arthritis 5 3. Pharmacological ·management of rh.eurna to id arthri ti.s . 8 a~ First line drugs . • . 8 5. Steroids .. ~ . • . 9 c. Second line drugs. • . 10 B. Animal Models for Rheumatoid Arthritis • 11 1. Adjuvant rat -.model . • • . 11 2. Antigen rabbit model • . 11 3. Collagen induced arthritis . 12 C. Human synovial Tissue and Cells in Culture. 12 1. Tissue . • . • . • • • 12 2. Cells and culture models . 13 a. Enzymatic release.... .adhesion . 13 b. Explant. • . 14 c. :Rheumatoid disease in culture. 16 3. Peptide modulators effects in culture 17 4. Antirheumatic drugs effects in cul- ture . • . ~ . • . 18 D. Role of Collagen . 19 1. Structure and synthesis .. 19 2. Types of collagens ••. 20 iv PAGE 3. Alteration of collagen types with di- sease. 4! • 23 4. Synovial collagen ...... 24 E. Gold in Rheumatoid Arthritis . 25 1. Efficacy and Toxicity-. 25 2. ~harmacokinetics . 26 a. Whole body-blood and tissue ..... 26 b. Cellular-aurosomes . 27 3. Pharmacodynami c..,.-mechani sm of action. 28 a. Protein interaction ........ 28 i. Albumin .... 28 ii. Collagen .... .•. 29 iii. Ly·sosomal enzymes 29 iv. Compliment ..... 29 b. Cell interaction . .. 30 i. Neutrophils . 30 ii. Macrophages ........ 30 iii. Lymphocytes . .... 31 4. Other gold compounds . .. 31 a. Gold thioglucose ......... 32 b. Auranofin. • .... 32 III. METHODS. 34 A. Materials . 34 B. Culture Method. 35 C. Cell Number Determinations .. 37 1. Hemocytometer ...... 37 2. Coulter counter 37 D. DNA Assays ..... 37 1. Ethidium- bromide. 37 2. [3H] thymidine . 38 E. Gold Determination - Atomic Absorption. 38 F. Collagen and Noncollagen Protein Synthesis. 39 G. Medium Collagen Assay for Type I and III Collagen . 40 1. Extraction. • . 40 2. Sample preparation for electrophoresis. 41 3. Electrophoresis procedure . 42 4. Quantitation. 43 a. Scanning procedure. 43 b. Fluorescence of band. 44 c. Radioactivity of bands. 45 v PAGE H. Carboxy Methyl Cellulose Chromatography of Collagen. 45 I. Purification of Type I and III Collagen Standards. 46 J. Phase Contrast PHotomicrographs. 48 K. Electron Microscope .... 49 1. Non-osmium procedure . 49 2. Osmium procedure .. 49 3. X-ray probe analysis . 50 L. Statistics . 50 IV. EXPERIMENTAL RESULTS . 53 A. MORPHOLOGY . 53 1. Light microscope . .... 53 2. Electron microscope ..... 56 a. In vivo and in vitro aurosomes 56 b. Genesis of the aurosome in culture. 59 c. Nuclear change . .. 59 B. BIOCHEMISTRY . 62 1. Proliferation .... 62 a. Cell number and size ..... 62 b. DNA content and rate of synthesis .•...... 65 2. Protein synthesis ...... 70 a. Noncollagen protein and colla- gen synthesis. .. 70 b. Collagen types . .. 74 i. Electrophoresis ... 74 11. Chromatography. .. 76 3. Reversibility .......... 80 4. Effect of GST on synovial cells and skin fibroblasts during log phase and confluency . 86 5. Anti-rheumatic drugs effect on synovial cells . 87 v. DISCUSSION . 90 VI. CONCLUSIONS. 105 VII. APPENDIX .. 107 VIII. REFERENCES 108 vi LIST OF TABLES TABLE PAGE 1 Effect of gold sodium thiomalate (GST) on cell viability. 55 2 Effect of latex beads and gold sodium thiomalate (GST) on proliferation and cell size . • . 3 Effect of gold sodium thiomalate (GST) on the percent of type III collagen synthesized by synovial cells . 81 4 Quantitation of gold associated with synovial and skin cell layers after exposures to gold sodium thiomalate (GST) containing medium •... 84 5 Recovery of biochemical parameters after gold sodium thiomalate (GST) exposed synovial cells are grown in medium without GST ..••••... 85 6 Effect of gold sodium thiomalate (GST) on bio­ chemical parameters of synovial and skin cells during log phase and confluency . • . • . 88 7 Effect of anti-rheumatic drugs on percent type III collagen synthesized by cultured synovial eel 1 s . 89 vii LIST OF FIGURES FIGURE PAGE 1 Phase contrast photographs of synovial cells ex- posed to gold sodium thiomalate (GST). 54 2 Electron microscope photomicrograph @f aurosomes and X-ray probe analysis . 5 7 3 In vivo and in vitro aurosomes • • • 5 8 4 Genesis of aurosomes .... 60 5 GST induced nuclear change. 61 6 Effect of gold sodium thiomalate (GST)on cell growth curve. 6 3 7 Effect of gold sodium thiomalate (GST) on cell number and size .......... 64 8 Dose dependent effect of gold sodium thiomalate on DNA accumulation . 68 9 Dose dependent effect of gold sodium thiomalate on DNA synthesis . 69 10 Dose dependent effect of gold sodium thiomalate on collagen and noncollagen protein synthesis . 71 11 Effect of gold sodium thiomalate on [3H]proline incorporation per cell and DNA.
Load more

Recommended publications
  • Wo 2009/082437 A9
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 2 July 2009 (02.07.2009) WO 2009/082437 A9 (51) International Patent Classification: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, C07D 207/08 (2006.01) A61K 31/402 (2006.01) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, C07D 207/09 (2006.01) A61P 5/26 (2006.01) NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, C07D 498/04 (2006.01) SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: PCT/US2008/013657 (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (22) International Filing Date: G M M N S D S L s z τ z U G Z M 12 December 2008 (12.12.2008) z w Eurasian (A M B γ KG> M D RU> τ (25) Filing Language: English TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (26) Publication Language: English M C M T N L N O P L P T R O S E S I s T R OAPI (30) Priority Data: B F ' B J ' C F ' C G ' C I' C M ' G A ' G N ' 0 G W ' M L ' M R ' 61/008,731 2 1 December 2007 (21 .12.2007) US N E ' S N ' T D ' T G ) - (71) Applicant (for all designated States except US): LIG- Declarations under Rule 4.17: AND PHARMACEUTICALS INCORPORATED [US/ — as to applicant's entitlement to apply for and be granted US]; 11085 N.
    [Show full text]
  • (Sodium Aurothiomalate Injection, Mfr. Std.) 10, 25 and 50 Mg/Ml Anti
    PRESCRIBING INFORMATION PrMYOCHRYSINE® (sodium aurothiomalate injection, Mfr. Std.) 10, 25 and 50 mg/mL Anti-Rheumatic Agent (disease modifying) sanofi-aventis Canada Inc. Date of Revision: 2150 St. Elzear Blvd. West November 29, 2007 Laval, Quebec H7L 4A8 Submission Control No.: 114637 s-a Version 2.0 dated NAME OF DRUG PrMYOCHRYSINE® Sodium aurothiomalate injection, Mfr. Std. 10, 25 and 50 mg/mL THERAPEUTIC CLASSIFICATION Anti-rheumatic agent (disease modifying) ACTIONS AND CLINICAL PHARMACOLOGY Sodium aurothiomalate exhibits anti-inflammatory, antiarthritic and immunomodulating effects. The predominant clinical effect of MYOCHRYSINE (sodium aurothiomalate) appears to be suppression of the synovitis in the active stage of the rheumatoid disease. The precise mechanism of action is unknown but it has been suggested that the drug may act by inhibiting cell-mediated and humoral immune mechanisms. Additional modes of action include alteration or inhibition of various enzyme systems, suppression of phagocytic activity of macrophage and polymorphonuclear leukocytes, and alteration of collagen biosynthesis. The metabolic fate of sodium aurothiomalate in humans is unknown but it is believed not to be broken down to elemental gold. It is very highly bound to plasma proteins. Sixty to 90% is excreted very slowly by the renal route while 10 to 40% is eliminated in the feces mostly via biliary secretion. The biologic half-life of gold following a single 50 mg dose of parenteral gold has been reported to range from 6 to 25 days. It increases following successive weekly doses. The appearance of clinical effect is slow. It may take at least 8 weeks to become significant and the maximum benefits may not be achieved for at least 6 months.
    [Show full text]
  • Treatment of Psoriatic Arthritis and Rheumatoid Arthritis with Disease Modifying Drugs — Comparison of Drugs and Adverse Reactions
    Treatment of Psoriatic Arthritis and Rheumatoid Arthritis with Disease Modifying Drugs — Comparison of Drugs and Adverse Reactions PHILIP S. HELLIWELL and WILLIAM J. TAYLOR for the CASPAR Study Group ABSTRACT. Objective. Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are chronic inflammatory diseases of the musculoskeletal system. Although it seems likely that these conditions have a different pathogene- sis, the drugs used to treat them are the same. Our study used a cross-sectional clinical database to com- pare drug use and side-effect profile in these 2 diseases. Methods. The CASPAR study collected data on 588 patients with PsA and 536 controls, 70% of whom had RA. Data on disease modifying drug treatments used over the whole illness were recorded, togeth- er with their outcomes, including adverse events, for RA and PsA. Results. For both diseases methotrexate (MTX) was the most frequently used disease modifying drug (39% of patients with PsA, 30% with RA), with over 70% of patients in both diseases still taking the drug. Other drugs were used with the following frequencies in PsA and RA, respectively: sulfasalazine 22%/13%, gold salts 7%/11%, antimalarial drugs 5%/14%, corticosteroids 10%/17%, and anti-tumor necrosis factor (TNF) drugs 6%/5%. Compared to RA, cyclosporine and anti-TNF agents were less like- ly to be ineffective in PsA. Compared to RA, subjects with PsA were less likely to be taking MTX and more likely to be taking anti-TNF agents. Hepatotoxicity with MTX was more common in PsA, and pul- monary toxicity with MTX was found more often in RA.
    [Show full text]
  • Hedonic Analysis of Arthritis Drugs
    This PDF is a selection from an out-of-print volume from the National Bureau of Economic Research Volume Title: Medical Care Output and Productivity Volume Author/Editor: David M. Cutler and Ernst R. Berndt, editors Volume Publisher: University of Chicago Press Volume ISBN: 0-226-13226-9 Volume URL: http://www.nber.org/books/cutl01-1 Publication Date: January 2001 Chapter Title: Hedonic Analysis of Arthritis Drugs Chapter Author: Iain M. Cockburn, Aslam H. Anis Chapter URL: http://www.nber.org/chapters/c7637 Chapter pages in book: (p. 439 - 462) Arthritis Drugs Iain M. Cockburn and Aslam H. Anis 11.1 Introduction This study examines the market for a group of drugs used to treat rheu- matoid arthritis (RA) during the period 1980-92. Rheumatoid arthritis is a painful, debilitating, and progressive disease which affects millions of people worldwide, with very substantial effects on health and the economy. Regrettably, in contrast to some other major health problems such as heart disease, depression, ulcers, and bacterial infections, this is an area where therapeutic innovations have thus far had comparatively little impact on physicians’ ability to reverse the disease. RA currently has no “cure” and the effectiveness of available treatments is limited. Compared to other drug classes the rate of new product introductions has been slow, and, at the time of writing, there have been no breakthroughs of the same order of significance as the discovery and development of SSRIs for treatment of depression, H, antagonists for ulcers, or ACE inhibitors for hypertension. Nonetheless, the market for RA drugs is far from static.
    [Show full text]
  • Should I Take Methotrexate
    I have never taken medication for rheumatoid arthritis before. Should I take methotrexate (Rheumatrex®) alone or with other disease- modifying anti-rheumatic drugs for rheumatoid arthritis? A Cochrane decision aid to discuss options with your doctor This decision aid is for you if: □ You are16 or older. □ Your doctor has told you that you have active rheumatoid arthritis (RA). □ You have never taken methotrexate or any disease-modifying anti-rheumatic drug before such as azathioprine (Imuran®), cyclosporine (Neoral®), gold therapy or sodium aurothiomalate (Myochrysine®), hydroxychloroquine (Plaquenil®), leflunomide (Arava®), penicillamine (Cuprimine®) sulfasalazine (Salazopyrin®, generics), tacrolimus (Prograf®) or others. What is Rheumatoid Arthritis (RA)? When you have rheumatoid arthritis, your immune system, which normally fights infection, attacks the lining of your joints making them inflamed. This inflammation causes your joints to be hot, swollen, stiff, and painful. The small joints of your hands and feet are usually affected first. If the inflammation goes on without treatment, it can lead to damaged joints. Once the joint is damaged it cannot be repaired, so treating rheumatoid arthritis early is important. What is Methotrexate? Methotrexate is a disease-modifying antirheumatic drug (DMARD). It is the most commonly used DMARD in rheumatoid arthritis. It works to control inflammation in your joints. Methotrexate is taken once per week and it comes in pill form or as an injection. Methotrexate only works while you are taking it. It will take 6 to 8 weeks for the methotrexate to work. It is important for you to keep taking the medicine. Your doctor may start you on a low dose and gradually increase your dose.
    [Show full text]
  • Report of the Expert Committee for the Selection and Inclusion Of
    Report of the Expert Committee / A Report of the Expert Committee for the Selection and Inclusion of Medicines in the Pan American Health Organization Strategic Fund – July 2013 Report of the Expert Committee for the Selection and Inclusion of Medicines in the Pan American Health Organization Strategic Fund – July 2013 PAHO HQ Library Cataloguing-in-Publication Data ***************************************************************************************** Pan American Health Organization. Report of the Expert Committee for the Selection and Inclusion of Medicines in the Pan American Health Organization Strategic Fund – July 2013. Washington, DC : PAHO, 2013. 1. Pharmaceutical Preparations. 2. Chronic Disease. 3. Cardiovascular Diseases. 4. Neoplasms. 5. Immunosuppressive Agents. 6. Complementary Therapies. 7. Americas. I. Title. II. PAHO Strategic Fund. ISBN 978-92-75-11814-6 (NLM Classification: QV55) The Pan American Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. Applications and inquiries should be addressed to the Department of Knowledge Management and Communications (KMC), Pan American Health plansOrganization, for new Washington,editions, and D.C.,reprints U.S.A. and ([email protected]). translations already available. The Department of Health Systems and Services (HSS) will be glad to provide the latest information on any changes made to the text, © Pan American Health Organization, 2013. All rights reserved. Publications of the Pan American Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. All rights are reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the Pan American Health Organization concerning the status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • Gold Levels Produced by Treatment with Auranofin and Sodium Aurothiomalate
    Ann Rheum Dis: first published as 10.1136/ard.42.5.566 on 1 October 1983. Downloaded from Annals ofthe Rheumatic Diseases, 1983, 42, 566-570 Gold levels produced by treatment with auranofin and sodium aurothiomalate D. LEWIS,' H. A. CAPELL,1 C. J. McNEIL,2 M. S. IQBAL,2 D. H. BROWN, 2 AND W. E. SMITH2 From the 1CentreforRheumatic Diseases, University DepartmentofMedicine, Baird Street, Glasgow G4 OEH, and the 2Department ofPure and Applied Chemistry, University ofStrathclyde, Glasgow GJ IXL SUMMARY Sixty-three patients with rheumatoid arthritis were randomly divided into 3 groups, and treated with either sodium aurothiomalate (Myocrisin), auranofin, or placebo. Gold levels in whole blood, plasma, and haemolysate were measured serially along with clinical and laboratory para- meters of efficacy. Auranofin produced a higher ratio of haemolysate to plasma gold than Myocrisin, and it appears that the affinity of the red cell for gold is reduced during therapy with auranofin. Gold levels did not correlate with changes in the pain score, erythrocyte sedimentation rate, and C-reactive protein, nor with the development of toxicity. In the Myocrisin group the haemolysate gold level achieved was dependent on the number of cigarettes smoked. In the auranofin group there was no such correlation, but the haemolysate gold level was higher for smokers than non-smokers. The likely action of gold is discussed. copyright. Gold compounds have been used in the treatment of The purpose of the present study was to measure rheumatoid arthritis for over 50 years, and theirplace the distribution ofgold in the blood of patients receiv- in clinical practice is firmly established.' 2 However, ing Myocrisin or auranofin, both in order to deter- there remains a need to monitor the use of these mine whether or not parameters such as haemolysate compounds very carefully to establish efficacy and to gold or the ratio of haemolysate to plasma gold are anticipate the onset of any toxic reaction which may correlated with efficacy or toxicity and to improve http://ard.bmj.com/ occur.
    [Show full text]
  • The Antiproliferative Effect of Sodium Aurothiomalate
    Annals of the Rheumatic Diseases, 1986; 45, 389-395 Cultured human cells can acquire resistance to the antiproliferative effect of sodium aurothiomalate A GLENNAS' 2 AND H E RUGSTAD' From the 'Division of Clinical Pharmacology, Institute for Surgical Research, Rikshospitalet, the National Hospital, and the 2Oslo Sanitetsforening Rheumatism Hospital, Oslo, Norway SUMMARY Cultured human epithelial cells (HE), grown as monolayers, acquired resistance to otherwise lethal concentrations (300 [tmol/l, culture medium) of sodium aurothiomalate during five months' exposure to stepwise increased concentrations of the drug. The resistance acquired was shown by exposure to drug concentrations ranging from 25 to 300 [mol/, resulting in 100% of the resistant cells (HeMy(,) surviving compared with controls. Only 13% of the sensitive parent cells survived when exposed to 300 [tmol/l for four days. The IHEMV, cells were also resistant to the antiproliferative effects of equimolar concentrations of thiomalic acid without gold. The cytosolic gold concentration and the association of '99Au with cytosolic proteins after gel filtration were similar in both cell lines after sodium aurothiomalate exposure to the exponentially growing cells. No synthesis of gold binding proteins of metallothionein character was observed in the HEMyo cells. The concentration of free thiomalate in the sonicates and cytosols of the HeMV, cells was decreased to 25-30% of the concentration found in the HE cells. Comparison with previous data for the cytosolic concentration of total thiomalate in the HE cells suggests that most of the cytosolic thiomalate present was free thiomalate. We conclude that the cells can develop resistance to the antiproliferative effect of sodium aurothiomalate, and that the resistance may be due to their capacity to maintain low concentrations of free thiomalate in the sonicates and cytosols.
    [Show full text]
  • Biochemical Indices Ofresponse to Hydroxychloroquine and Sodium Aurothiomalate in Rheumatoid Arthritis 481
    Ann Rheum Dis: first published as 10.1136/ard.40.5.480 on 1 October 1981. Downloaded from Annals of the Rheumatic Diseases, 1981, 40, 480-488 Biochemical indices of response to hydroxychloroquine and sodium aurothiomalate in rheumatoid arthritis J. S. DIXON, M. E. PICKUP, H. A. BIRD, M. R. LEE, V. WRIGHT, AND W. W. DOWNIE From the Clinical Pharmacology Unit, Royal Bath Hospital, Harrogate, and the University Department of Medicine, General Infirmary, Leeds SUMMARY Biochemical and clinical changes have been monitored in 30 patients with rheumatoid arthritis treated with either hydroxychloroquine or sodium aurothiomalate over a period of 6 months. Acute-phase reactants improved in both treatment groups, while serum sulphydryl and serum histidine improved only in the gold-treated patients. Correlation matrices were constructed from mean clinical and biochemical data at successive clinic visits. Correlations obtained with gold were more frequent and of a higher level of significance than those obtained with hydroxychloro- quine at the doses we studied. This lends support to the use of correlation matrices as a screening test for potential long-term antirheumatoid activity of drugs in man. copyright. In an attempt to define biochemical and clinical 39 to 66 years; 2 male, aged 31 and 49 years) were changes that occur when patients with rheumatoid allocated to HCQ therapy, and a further 15 patients arthritis are exposed for the first time to 'specific (11 female, mean age 52 7, range 36 to 67 years; antirheumatoid' therapy, and to see if these changes 4 male, mean age 54*5, range 45 to 64 years) were differ between drugs we have performed serial allocated to gold therapy.
    [Show full text]
  • Hydroxychloroquine and Sulphasalazine Alone and in Combination in Rheumatoid Arthritis: a Randomised Double Blind Trial
    Annals of the Rheumatic Diseases 1993; 52: 711-715 71 Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial Karen Lisbeth Faarvang, Charlotte Egsmose, Peter Kryger, Jan P0denphant, Margrethe Ingeman-Nielsen, Troels M0rk Hansen Abstract and hydroxychloroquine was superior to Objectives-To compare the effects of treatment with a single drug. The two drugs hydroxychloroquine and sulphasalazine were chosen because of their low incidence of alone and in combination in rheumatoid serious side effects. In addition, we aimed to arthritis. determine whether previous treatment with Methods-A six month randomised, gold salts or penicillamine affected the multicentre, double blind trial with three outcome. Finally, the selection of patients for parallel groups was performed. Ninety one the study from the total population of patients outpatients with active rheumatoid with RA at the three participating rheumato- arthritis were included. Monthly assess- logical clinics was recorded. ments of erythrocyte sedimentation rate, morning stiffness, number of swollen joints, a pain score, and global assess- Patients and methods ments were carried out. Radiographs of PATIENTS hands and wrists were taken before and During the inclusion period 776 patients with after the trial. RA were registered in the three participating Results-Sixty two patients completed the departments. Ninety one of these met the study. The 29 withdrawals caused no criteria for inclusion in the trial. They all had evident bias, and there was no difference RA defined according to the American in side effects among the three groups. All Rheumatism Association 1958 criteria.' The Department of variables improved significantly with mean age was 61 years (range 18-82) and the Rheumatology, Kong time.
    [Show full text]
  • Sodium Aurothiomalate
    Wirral University Teaching Hospital NHS Foundation Trust Shared Care Guideline Sodium aurothiomalate (i.m gold) for rheumatoid arthritis and other rheumatological diseases (Adults) It is vital for safe and appropriate patient care that there is a clear understanding of where clinical and prescribing responsibility rests between Consultants and General Practitioners (GPs). This guideline reinforces the basic premise that: When clinical and / or prescribing responsibility for a patient is transferred from hospital to GP, the GP should have full confidence to prescribe the necessary medicines. Therefore, it is essential that a transfer of care involving medicines that a GP would not normally be familiar with, should not take place without the “sharing of information with the individual GP and their mutual agreement to the transfer of care.” These are not rigid guidelines. On occasions, Consultants and GPs may agree to work outside of this guidance. As always, the doctor who prescribes the medication has the clinical responsibility for the drug and the consequences of its use. Indications: Dosage and administration: Sodium aurothiomalate (gold) is Given by deep intramuscular injection. used in the management of active Test dose 10 mg must be given in clinic followed by 30 mins progressive rheumatoid arthritis observation to look for signs of allergic reaction, followed by 50 mg once weekly until there is definite evidence of remission, then reduced to 50 mg every 4 weeks continued for up to 5 years after complete remission, dose to be reduced
    [Show full text]
  • Hydroxychloroquine and Sulphasalazine Alone and Ann Rheum Dis: First Published As 10.1136/Ard.52.10.711 on 1 October 1993
    Annals of the Rheumatic Diseases 1993; 52: 711-715 71 Hydroxychloroquine and sulphasalazine alone and Ann Rheum Dis: first published as 10.1136/ard.52.10.711 on 1 October 1993. Downloaded from in combination in rheumatoid arthritis: a randomised double blind trial Karen Lisbeth Faarvang, Charlotte Egsmose, Peter Kryger, Jan P0denphant, Margrethe Ingeman-Nielsen, Troels M0rk Hansen Abstract and hydroxychloroquine was superior to Objectives-To compare the effects of treatment with a single drug. The two drugs hydroxychloroquine and sulphasalazine were chosen because of their low incidence of alone and in combination in rheumatoid serious side effects. In addition, we aimed to arthritis. determine whether previous treatment with Methods-A six month randomised, gold salts or penicillamine affected the multicentre, double blind trial with three outcome. Finally, the selection of patients for parallel groups was performed. Ninety one the study from the total population of patients outpatients with active rheumatoid with RA at the three participating rheumato- arthritis were included. Monthly assess- logical clinics was recorded. ments of erythrocyte sedimentation rate, morning stiffness, number of swollen joints, a pain score, and global assess- Patients and methods ments were carried out. Radiographs of PATIENTS hands and wrists were taken before and During the inclusion period 776 patients with after the trial. RA were registered in the three participating Results-Sixty two patients completed the departments. Ninety one of these met the study. The 29 withdrawals caused no criteria for inclusion in the trial. They all had evident bias, and there was no difference RA defined according to the American in side effects among the three groups.
    [Show full text]